主页 > 医学讨论 >
【medical-news】羟基氯喹治疗类风湿性关节炎可预
Last Updated: 2007-07-10 16:55:02 -0400 (Reuters Health)
NEW YORK (Reuters Health) - Among patients with rheumatoid arthritis, long-term treatment with hydroxychloroquine appears to reduce the incidence of diabetes, according to a preliminary communication in the Journal of the American Medical Association for July 11.
Previous evidence from animal studies suggests that hydroxychloroquine has an antidiabetic effect. Among human patients, the antimalarial drug can cause hypoglycemia and reduce glycated hemoglobin levels.
To directly examine the link between hydroxychloroquine and diabetes, Dr. Mary Chester M. Wasko, from the University of Pittsburgh, and her colleagues analyzed data from a prospective, multicenter observational study spanning the period between 1983 and 2004. The 4905 participating middle-aged adults with rheumatoid arthritis were not diabetic at baseline. Roughly one-third (1808) had taken hydroxychloroquine for some period of time during the study, with duration of treatment averaging 3.1 years.
Incidence rates per 1000 patient-years of observation were 8.9 for never-users of hydroxychloroquine and 5.2 for ever-users (p < 0.001). In multivariable analysis, the hazard ratio for incident diabetes was 0.62 for the hydroxychloroquine group compared to the others.
Moreover, the degree of protection increased over time. The adjusted hazard ratio was 0.22 for the 384 patients who used the drug for more than 4 years (p < 0.001), a finding that supports "a biological action of this drug on glucose metabolism," the authors say.
Furthermore, the investigators report, the reduction of risk was on a par with traditional antidiabetic drugs, including rosiglitazone, metformin, acarbose, and ramipril.
Dr. Wasko and her associates recommend consideration of hydroxychloroquine as a standard component of treatment for rheumatoid arthritis.
They don't believe that the antihyperglycemic trait of hydroxychloroquine is limited to patients with autoimmune disease. They therefore encourage further research "to evaluate the potential role of hydroxychloroquine as a preventive agent for diabetes among high-risk individuals in the general population."
JAMA 2007; 298:187-193.
http://www.reutershealth.com/archive/2007/07/10/professional/links/20070710epid006.html Hydroxychloroquine treatment of rheumatoid arthritis may prevent diabetes
羟基氯喹治疗类风湿性关节炎可预防糖尿病
Last Updated: 2007-07-10 16:55:02 -0400 (Reuters Health)
最后更新2007-07-10 16:55:02 -0400 (路透健康)
NEW YORK (Reuters Health) - Among patients with rheumatoid arthritis, long-term treatment with hydroxychloroquine appears to reduce the incidence of diabetes, according to a preliminary communication in the Journal of the American Medical Association for July 11.
纽约（路透社健康版）──据7月11日《美国医学会杂志 》发表前一则消息称，在长期应用羟基氯喹的类风湿性关节炎患者中，糖尿病的发病率下降。
Previous evidence from animal studies suggests that hydroxychloroquine has an antidiabetic effect. Among human patients, the antimalarial drug can cause hypoglycemia and reduce glycated hemoglobin levels.
以前的动物研究表明，羟基氯喹具有抗糖尿病作用。而在人类，羟基氯喹不仅可以治疗疟疾，还可引起低血糖，并降低糖化血红蛋白水平。
To directly examine the link between hydroxychloroquine and diabetes, Dr. Mary Chester M. Wasko, from the University of Pittsburgh, and her colleagues analyzed data from a prospective, multicenter observational study spanning the period between 1983 and 2004. The 4905 participating middle-aged adults with rheumatoid arthritis were not diabetic at baseline. Roughly one-third (1808) had taken hydroxychloroquine for some period of time during the study, with duration of treatment averaging 3.1 years.
匹兹堡大学的Mary Chester M. Wasko博士和她的同事为了明确羟基氯喹和糖尿病之间的关系，对一项前瞻性多中心观察性研究的数据进行分析。该研究于1983年开始，2004年结束。研究开始时4905名类风湿性关节患者均未患糖尿病。大约三分之一患者（1808）在研究的某个时期服用了羟基氯喹，平均服药时间3.1年。
Incidence rates per 1000 patient-years of observation were 8.9 for never-users of hydroxychloroquine and 5.2 for ever-users (p < 0.001). In multivariable analysis, the hazard ratio for incident diabetes was 0.62 for the hydroxychloroquine group compared to the others.
未服用羟基氯喹的患者，糖尿病发病率为8.9/1000人年，而服过羟基氯喹的患者糖尿病发病率为5.2/1000人年(p < 0.001)。在多变量分析中，羟基氯喹组与未服用该药的患者相比，糖尿病发病危险比为0.62。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-18 17:12
医学,生命科学网